Tvardi Therapeutics (TVRD) Net Cash Flow: 2013-2017
Historic Net Cash Flow for Tvardi Therapeutics (TVRD) over the last 5 years, with Dec 2017 value amounting to -$3.1 million.
- Tvardi Therapeutics' Net Cash Flow fell 141.75% to -$3.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$3.4 million, marking a year-over-year decrease of 51.96%. This contributed to the annual value of -$15.8 million for FY2024, which is 50.77% down from last year.
- According to the latest figures from Q4 2017, Tvardi Therapeutics' Net Cash Flow is -$3.1 million, which was down 230.64% from $2.4 million recorded in Q3 2017.
- In the past 5 years, Tvardi Therapeutics' Net Cash Flow ranged from a high of $67.9 million in Q3 2015 and a low of -$96.0 million during Q4 2015.
- Its 3-year average for Net Cash Flow is -$3.6 million, with a median of -$3.7 million in 2015.
- Its Net Cash Flow has fluctuated over the past 5 years, first surged by 12,905.85% in 2014, then tumbled by 1,575.65% in 2015.
- Tvardi Therapeutics' Net Cash Flow (Quarterly) stood at -$5.4 million in 2013, then fell by 6.58% to -$5.7 million in 2014, then tumbled by 1,575.65% to -$96.0 million in 2015, then skyrocketed by 107.74% to $7.4 million in 2016, then plummeted by 141.75% to -$3.1 million in 2017.
- Its Net Cash Flow was -$3.1 million in Q4 2017, compared to $2.4 million in Q3 2017 and $4.1 million in Q2 2017.